Companion Diagnostics Celcuity's focus on targeted PI3K/AKT/mTOR therapies for HR+/HER2- breast cancer creates strong demand for biomarker testing and companion diagnostics. Opportunities exist to partner with diagnostic labs or assay providers for PIK3CA status testing and integrated trial enrollment solutions.

Trial Partnerships As a clinical-stage company with ongoing Phase 1b/2 work and potential regulatory milestones, there is a clear path to engage CROs, trial management systems, and patient recruitment networks to optimize study execution and data quality.

Financing Support Celcuity recently expanded its financing via convertible notes, signaling ongoing capital needs. Consider offering investor relations programs, treasury management, and market analytics to support fundraising, pricing, and communications with investors.

Digital & Data The existing tech stack shows emphasis on CRM, cloud, and marketing tools. There is potential to provide digital infrastructure enhancements, data integration, cybersecurity, and regulatory-compliant cloud services to streamline operations and accelerate go-to-market readiness.

Commercial Alliances With potential blockbuster prospects in a large market and opportunities for licensing or co-development, Celcuity could be an attractive partner for strategic collaborations, manufacturing scale-up, global commercialization, or companion diagnostic co-development.